Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)
Results of 31 controlled randomized studies of insulin glargine given to patients with diabetes mellitus are reviewed to evaluate the frequency of malignantneoplasms. 52 tumours were diagnosed in 45 (0.8%) patients on insulin glargine therapy and 48 tumors in 46 (0.9%) patients using other insulins(...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2010-03-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6022 |
| _version_ | 1797255276103991296 |
|---|---|
| author | Marina Vladimirovna Shestakova Irina Vladimirovna Glinkina |
| author_facet | Marina Vladimirovna Shestakova Irina Vladimirovna Glinkina |
| author_sort | Marina Vladimirovna Shestakova |
| collection | DOAJ |
| description | Results of 31 controlled randomized studies of insulin glargine given to patients with diabetes mellitus are reviewed to evaluate the frequency of malignantneoplasms. 52 tumours were diagnosed in 45 (0.8%) patients on insulin glargine therapy and 48 tumors in 46 (0.9%) patients using other insulins(mostly NPX insulin). The incidence of breast cancer was equal (0.1%) in both groups (4 and 6 cases respectively). These data indicate thatthe use of insuline glargine does not increase the risk of malignancy, e.g. breast cancer. |
| first_indexed | 2024-03-08T15:22:16Z |
| format | Article |
| id | doaj.art-591ef5e54f8e4c339a69acbcf691130d |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2024-04-24T22:03:16Z |
| publishDate | 2010-03-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-591ef5e54f8e4c339a69acbcf691130d2024-03-20T11:47:55ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782010-03-01131889010.14341/2072-0351-60225980Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)Marina Vladimirovna Shestakova0Irina Vladimirovna Glinkina1Endocrinological Research Centre, MoscowI.M. Sechenov Moscow Medical Academy, MoscowResults of 31 controlled randomized studies of insulin glargine given to patients with diabetes mellitus are reviewed to evaluate the frequency of malignantneoplasms. 52 tumours were diagnosed in 45 (0.8%) patients on insulin glargine therapy and 48 tumors in 46 (0.9%) patients using other insulins(mostly NPX insulin). The incidence of breast cancer was equal (0.1%) in both groups (4 and 6 cases respectively). These data indicate thatthe use of insuline glargine does not increase the risk of malignancy, e.g. breast cancer.https://www.dia-endojournals.ru/jour/article/view/6022diabetes mellitusinsulin glarginemalignant neoplasmsbreast cancer |
| spellingShingle | Marina Vladimirovna Shestakova Irina Vladimirovna Glinkina Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506) Сахарный диабет diabetes mellitus insulin glargine malignant neoplasms breast cancer |
| title | Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506) |
| title_full | Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506) |
| title_fullStr | Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506) |
| title_full_unstemmed | Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506) |
| title_short | Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506) |
| title_sort | insulin glargine does not increase the risk of malignancy synopsis of the article combined randomised controlled trial experience of malignancies in studies using insulin glargine byhome p d amp lagarenne p diabetologia 2009 vol 52 12 2499 2506 |
| topic | diabetes mellitus insulin glargine malignant neoplasms breast cancer |
| url | https://www.dia-endojournals.ru/jour/article/view/6022 |
| work_keys_str_mv | AT marinavladimirovnashestakova insulinglarginedoesnotincreasetheriskofmalignancysynopsisofthearticlecombinedrandomisedcontrolledtrialexperienceofmalignanciesinstudiesusinginsulinglarginebyhomepdamplagarennepdiabetologia2009vol521224992506 AT irinavladimirovnaglinkina insulinglarginedoesnotincreasetheriskofmalignancysynopsisofthearticlecombinedrandomisedcontrolledtrialexperienceofmalignanciesinstudiesusinginsulinglarginebyhomepdamplagarennepdiabetologia2009vol521224992506 |